PROM1 and pancreatic neoplasm: To study if adipocytes enriched for CD133+ therapy resistant population in pancreatic tumors, we next treated MIA-PACA2 (pancreatic cancer cells with negligible CD133+ population) with conditioned media from patient derived adipocytes.